Intelligent Wearable Insulin Pump System for Personalized Diabetes Management

Publication ID: 24-11857757_0005_PTD
Published: November 07, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Intelligent Wearable Insulin Pump System for Personalized Diabetes Management,” Published Technical Disclosure No. 24-11857757_0005_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11857757_0005_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,757.

Summary of the Inventive Concept

An innovative wearable insulin pump system incorporating AI-powered dosing algorithms, real-time glucose monitoring, and personalized insulin delivery profiles, enabling optimal glucose control and improved quality of life for diabetes patients.

Background and Problem Solved

The original patent addressed the need for wearable insulin pumps, but limitations in dosing accuracy, user interface, and predictive capabilities remain. This new inventive concept tackles these limitations by integrating advanced technologies to provide a more effective, user-centric, and adaptive insulin delivery system.

Detailed Description of the Inventive Concept

The intelligent wearable insulin pump system comprises a transcutaneous patch pump with an integrated AI-powered dosing algorithm, a real-time glucose monitoring sensor, and a user interface for personalized insulin delivery profiles. The system adapts to the user's lifestyle and provides predictive insulin dosing recommendations. The patch pump features a micro-needle array for minimally invasive drug delivery, a piezoelectric actuator for precise dosing control, and a wireless communication module for real-time data transmission to a remote monitoring system. The system analyzes user data on meal intake, physical activity, and glucose levels using deep learning algorithms to identify patterns and correlations, generating personalized insulin dosing recommendations for optimal glucose control.

Novelty and Inventive Step

The new inventive concept introduces AI-powered dosing algorithms, real-time glucose monitoring, and personalized insulin delivery profiles, which are not present in the original patent. The integration of these advanced technologies enables a paradigm shift in wearable insulin pump systems, providing a more effective, user-centric, and adaptive insulin delivery system.

Alternative Embodiments and Variations

Alternative embodiments could include variations in the AI-powered dosing algorithm, such as using different machine learning models or incorporating additional data sources. Other variations could include different types of sensors, such as continuous glucose monitoring or blood glucose meters, or alternative user interfaces, such as voice-controlled or augmented reality-based systems.

Potential Commercial Applications and Market

The intelligent wearable insulin pump system has significant commercial potential in the diabetes management market, with potential applications in hospitals, clinics, and home care settings. The system could be marketed to healthcare providers, patients, and caregivers, offering improved glucose control, enhanced patient outcomes, and reduced healthcare costs.

CPC Classifications

SectionClassGroup
A A61 A61M5/14248
A A61 A61B5/14865
A A61 A61M5/1413
A A61 A61M5/158
A A61 A61M5/168
A A61 A61M5/1684
A A61 A61M5/16827
A A61 A61M5/172
A A61 A61M5/1723
A A61 A61M5/5086
A A61 A61M2005/14252
A A61 A61M2005/14256
A A61 A61M2005/14533
A A61 A61M2005/1586
A A61 A61M2205/18
A A61 A61M2205/3317
A A61 A61M2205/3331
A A61 A61M2205/582
A A61 A61M2207/00

Field of Art

Medical device engineering, specifically wearable medication delivery systems with a focus on insulin pump technologies, encompassing microfluidics, sensor integration, and drug delivery mechanisms

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer with expertise in medical device design, microelectronics, sensor technologies, and software integration for personalized medical systems, typically holding a master's or PhD with 3-5 years of industry experience

Obviousness Rationale

A PHOSITA would recognize that the PTD's AI-powered dosing and personalized delivery mechanisms are logical extensions of existing wearable insulin pump technologies, representing predictable improvements using known machine learning techniques to enhance medication management. The integration of real-time monitoring, adaptive algorithms, and wireless communication represents incremental innovation within the established technological landscape of diabetes management devices.

Obvious Combinations & Variations

Source Patent Element
Patch pump configured for transcutaneous medication delivery with cartridge-based dosing mechanism
PTD Variation
Addition of AI-powered dosing algorithm and real-time glucose monitoring sensor
Obviousness Reasoning
Predictable application of machine learning to existing medication delivery systems, representing a known technique for improving medical device functionality
Source Patent Element
Medication infusion device with controllable pusher mechanism
PTD Variation
Piezoelectric actuator for precise dosing control with wireless communication module
Obviousness Reasoning
Obvious design optimization using known microelectromechanical systems (MEMS) technologies to enhance dosing precision and data transmission
Source Patent Element
Wearable insulin pump with basic user interface
PTD Variation
Cloud-based analytics platform and mobile application for personalized insulin delivery profiles
Obviousness Reasoning
Straightforward digital transformation of medical device interface using standard software integration techniques and cloud computing paradigms
Source Patent Element
Transcutaneous medication delivery system
PTD Variation
Micro-needle array for minimally invasive drug delivery with deep learning-based dosing recommendations
Obviousness Reasoning
Incremental improvement combining known micro-needle technologies with machine learning algorithms for enhanced drug delivery precision
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857757 and the disclosed technical variations, a person of ordinary skill in the art would find the claimed innovations of an AI-powered, personalized insulin delivery system to be obvious and lacking inventive step, thereby rendering such claims unpatentable under 35 U.S.C. § 103 as predictable variations within the existing technological domain of wearable medication delivery systems.

Original Patent Information

Patent NumberUS 11,857,757
TitleSystems and methods for delivering microdoses of medication
Assignee(s)Tandem Diabetes Care Switzerland Sàrl